Undetected lymph node metastases in presumed early stage NSCLC SABR patients

LAUR Repository

Show simple item record

dc.contributor.author Diab, Khalil
dc.contributor.author Cerra-Franco, Alberto
dc.contributor.author Lautenschlaeger, Tim
dc.date.accessioned 2019-02-13T09:58:33Z
dc.date.available 2019-02-13T09:58:33Z
dc.date.copyright 2016 en_US
dc.date.issued 2019-02-13
dc.identifier.issn 1744-8328 en_US
dc.identifier.uri http://hdl.handle.net/10725/10029
dc.description.abstract Introduction: Stereotactic body radiation therapy (SBRT, also called stereotactic ablative body radiation SABR) is the treatment of choice for many patients with early-stage non-small cell lung cancer (NSCLC), including those who are unfit for surgery or refuse surgery. Areas covered: In an effort to develop optimal staging for the evaluation of SBRT candidates, we review the performance of available lymph node staging methods, as well as risk factors for lymph node involvement. Pubmed was searched to identify relevant literature. Current staging methods for NSCLC, including Positron Emission Tomography/Computed Tomography(PET/CT) and endobronchial ultra sound (EBUS), have limited sensitivities. Expert commentary: There are several factors, including primary tumor location, tumor size, and histology that are possibly associated with the sensitivity of PET/CT to detect mediastinal lymph node metastasis. Small lymph node metastases typically remain undetected by PET/CT. Therefore invasive nodal staging procedures are indicated for most presumed early-stage NSCLC patients, but these also have limited sensitivity. Occult lymph node metastasis is associated with adverse outcome in NSCLC. Moreover, there is overwhelming evidence that certain patients who have lymph node metastases detected at the time of surgery derive an overall survival benefit from adjuvant therapies. It remains to be determined if improved detection of lymph node metastases in SABR candidates can indeed improve prognosis. en_US
dc.language.iso en en_US
dc.title Undetected lymph node metastases in presumed early stage NSCLC SABR patients en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201900605 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Expert Review of Anticancer Therapy en_US
dc.journal.volume 16 en_US
dc.journal.issue 8 en_US
dc.article.pages 869-875 en_US
dc.keywords SBRT en_US
dc.keywords SABR en_US
dc.keywords SBRT lymph node metastases en_US
dc.keywords Occult metastases en_US
dc.keywords EBUS en_US
dc.keywords EUS en_US
dc.keywords Staging en_US
dc.keywords Non-small cell lung cancer en_US
dc.keywords CT en_US
dc.keywords PET en_US
dc.identifier.doi https://doi.org/10.1080/14737140.2016.1199279 en_US
dc.identifier.ctation Cerra-Franco, A., Diab, K., & Lautenschlaeger, T. (2016). Undetected lymph node metastases in presumed early stage NSCLC SABR patients. Expert review of anticancer therapy, 16(8), 869-875. en_US
dc.author.email khalil.diab@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.tandfonline.com/doi/abs/10.1080/14737140.2016.1199279 en_US
dc.orcid.id https://orcid.org/0000-0001-9255-7575 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account